Hospital-acquired Infection Diagnostics Market Overview:
The Hospital-acquired Infection Diagnostics Market was valued at $2,571 million in 2016, and is expected to reach at $4,311 million by 2023, registering a CAGR of 7.5% from 2017 to 2023. Hospital-acquired infections are infections caused by bacterial, viral, and fungal pathogens. These infections can be acquired in clinical settings such as nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can be acquired from an infected patient, outside environment, or from the staff of that facility. The hospital-acquired infection diagnostics market is primarily driven by the increase in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities. However, the decline in hospital-acquired infections in the developed countries such as the U.S., Germany, and UK impedes the market growth.
The hospital-acquired infection diagnostics market is segmented based on product, test type, application, infection type, end user and region. Based on product this market is segmented into instrument and reagents and consumables. Based on test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. Based on application, the market is divided into disease testing and drug resistance testing. Further, based on infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others. Based on end user this market is segmented into hospital, clinics, ambulatory surgery centers (ASC) and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Drivers, Restraints, and Opportunities
Factors that accelerate the growth of the hospital-acquired infection diagnostics market are the rise in geriatric population base coupled with the demand for hospital-acquired infection diagnostics from middle and low-income economies.
Impact Analysis: Drivers & Restraints
However, lack of awareness regarding hospital-acquired infection and decrease in prevalence of HAI in the developed countries act as a restraint for the growth of the market.
India Hospital Acquired Infection Diagnostics Market
India is expected to grow rapidly in hospital acquired infection diagnostics market owing to the increase in prevalence of nosocomial infections such as surgical site infections and blood stream infections. According to Indian Journal of Basic and Applied Medical Research, India reported an overall growth rate for hospital acquired infections of 4.4% after conducting a research on 10,835 patients in various clinical settings.
Global Hospital Acquired Infection Diagnostics Market, by Type
Molecular diagnostics accounted for about one fourth share of the total market share in 2016 and is expected to grow with a high CAGR during the forecast period. This is due to advantages of molecular diagnostics for infectious diseases such as detection of lower amounts of infectious agents and also provides an effective yet simple tool to establish efficacy of therapy and modify treatment when appropriate.
The report provides a comprehensive analysis of the key players operating in the global hospital-acquired infection diagnostics market such as Abbott Laboratories, AdvanDX, Alere Inc., AstraZeneca plc, Bayer Schering Pharma LLC, Becton Dickinson and Company, Cepheid Inc., Roche AG, Daiichi Sankyo, and Hologic, Inc.
The other players of the global hospital-acquired infection diagnostics market include GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Meridien, Pfizer, and Seegene.
- The study provides an in-depth analysis of the global hospital-acquired infection diagnostics market, with current trends and future estimations to elucidate the imminent investment pockets.
- A quantitative analysis from 2016 to 2023 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
- Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the market.
- Porter’s Five Forces model is expected to interpret the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.
Hospital-acquired Infection Diagnostics Marketkey Segments:
- Instrument and Reagents
By Test Type
- Molecular Diagnostics
- Disease Testing and
- Drug-Resistance Testing
By Infection Type
- Hospital Acquired Pneumonia
- Bloodstream Infections
- Surgical Site Infections
- Gastrointestinal Infections
- Urinary Tract Infections (UTI)
- Ambulatory Surgery Centers (ASC)
- North America
- Rest of Europe
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- Rest of LAMEA